openPR Logo
Press release

Familial Chylomicronemia Syndrome Treatment Market

10-24-2017 04:30 PM CET | Health & Medicine

Press release from: Pharamceutical

Familial Chylomicronemia Syndrome is a genetic condition characterized by an inability of the body to digest fats mainly triglyceride. In Familial Chylomicronemia Syndrome, the lipoprotein lipase (LPS) is not functional, which is the enzyme that breaks down chylomicrons in the blood. The most distinctive sign of Familial Chylomicronemia Syndrome is the appearance of fatty blood on the skin, mainly owing to high level of fat in the body. People with high level of triglycerides are more subjected to FCS. According to the Familial Chylomicronemia Syndrome (FCS) Foundation report, in 2017, around 30 million people suffer from rare diseases, accounted for every 1 out of 10 people in the U.S, and also 95% of rare diseases have no Food and Drug Administration (FDA) approved treatment. Familial Chylomicronemia Syndrome is a rare disorder that affect small population worldwide. According to a report by National Organization for Rare Disorders (NORD), in 2017, FCS is more prevalent in French community and certain communities of the Netherland, where the prevalence is as high as every 19 to 20 per one million individuals.

Request For Sample Copy@
https://www.coherentmarketinsights.com/insight/request-sample/946

Severe complications associated with FCS include fatty liver diseases, enlarged liver, enlarged spleen, and pancreatitis, which can be life-threatening. In pancreatitis, pancreas produces hormones insulin, which helps to digest food and regulates blood sugar level. It is characterized by inflammation of pancreas, which is extremely painful and can be severe. Frequent attacks of pancreatitis may lead to long-term organ damage or death. Due to the rarity of the condition, the clinical progression of this syndrome is not well understood, which is creating an opportunity for the Familial Chylomicronemia Syndrome treatment market player in near future.

With FCS, the triglyceride level can increase up to 20 to 30 time as compared to normal individuals, even with medication of a low-fat diet. Researchers are working to develop a therapy with a potential to reduce the level of ApoC-III in the blood. ApoC-III has proven to be a protein that regulate triglycerides level in the human body. Thus, reducing the amount of ApoC-III may help to regulate the elevated level of triglyceride, which is a significant risk factor for pancreatitis.

Non-renewal of Glybera and launch of Volanesorsen to govern the total Familial Chylomicronemia Syndrome treatment market growth

In September 2017, Akcea Therapeutics Inc., a subsidiary of Ionis Pharmaceutical Inc., announced the filing of New Drug Submission (NDS) to Health Canada for Volanesorsen with the focus to develop and commercialize drugs to treat severe cardio metabolic disease caused by lipid disorder. Volanesorsen is designed to decrease the production of ApoC-III protein production in liver, which plays a vital role in the regulation of plasma TG. The Health Canada granted priority review to the drug for the treatment of Familial Chylomicronemia Syndrome in Canada, which could help accelerate the access of this medicine to the people of Canada suffering from FCS and is expected to fuel the growth of Familial Chylomicronemia Syndrome treatment market in this region. Akcea Therapeutics achieved successful results in its phase 3 trails - APPROACH Study and is currently conducting the APPROACH Open Label Study to further evaluate is efficacy with extended administration of the drug in FCS patients.

Glybera, a gene therapy, is designed to restore the LPL enzyme required to clear the fat-carrying chylomicron particles from the intestine. It is a one-time gene therapy treatment, which includes a series of 60 intramuscular injections in the legs. In October 2012, the European commission granted marketing authorization of Glybera under exceptional circumstances as a treatment for small subsets of adult patients diagnosed with familial LPL deficiency, which was confirmed by genetic testing. In April 2017, uniQure announced non-renewal of Glybera gene therapy authorization in Europe, which is scheduled to expire in October 2017. The non-renewal of Glybera’s marketing authorization in Europe is expected to affect the overall market of FCS.

Get More Details On this Report:
https://www.coherentmarketinsights.com/ongoing-insight/familial-chylomicronemia-syndrome-treatment-market-946

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com
Visit our news Website: http://www.coherentnews.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Familial Chylomicronemia Syndrome Treatment Market here

News-ID: 783965 • Views: 395

More Releases from Pharamceutical

Interventional Oncology Solutions Market Ablation Radiofrequency Ablation, Cryo …
Interventional oncology is a field of medical science, which includes treatment and diagnosis of cancer and other problems related to cancer using minimally invasive procedures. Interventional oncology uses various techniques such as Ultrasound, computed tomography, X-ray, and magnetic resonance imaging (MRI) to treat tumors located in various organs of the body. Interventional oncology procedures are usually used to treat metastatic or primary cancer. These procedures can be used to treat
Congestive Heart Failure Drugs Market, by Drug Type ACE Inhibitors, Angiotensin …
Major driver for growth of the congestive heart failure drugs market is the robust pipeline of drugs under development. For instance, furosemide injection solution (SCP-101) sponsored by Johns Hopkins University in collaboration with Scpharmaceuticals Inc. was in phase 2 clinical trials in 2015, this injection is indicated for treatment of heart failure. Furosemide and Azosemide sponsored by Hyogo College of Medicine has completed phase 4 clinical trials in 2016, these
New improved medication with lesser side effects will drive the insomnia therape …
Benzodiazepines (BZP) such as temazepam and diazepam are the commonly prescribed medication for insomnia. Though these medications are effective, prolonged use of these drugs may cause cognitive impairment, dependency and addiction. The launch of novel drugs such as Intermezzo (2014), tasimelteon (2014) have created a meteoric growth in G7 countries in the insomnia therapeutics and is expected market over the forecast period. Intermezzo (2014), are used in small doses and administered
Antiepileptic Drugs Market - Global Industry Insights,
Antiepileptic Drugs Market Regional Analysis North America and Europe are expected to witness significant growth in the market over the forecast period due to robust pipeline for epilepsy treatment and individual efforts by leading manufacturers. For instance, Pfizer, Inc. entered into partnership with Epilepsy Foundation to find solutions for generic forms of epilepsy and associated neurological disorders in 2014. Asia Pacific region is expected to show positive developments over the forecast

All 5 Releases


More Releases for Familial

Heterozygous Familial Hypercholesterolemia (heFH) Therapeutics - Pipeline Analys …
Heterozygous familial hypercholesterolemia (HeFH) is an inherited genetic disorder that affects the body’s ability to control cholesterol. It is characterized by very high LDL (low density lipoprotein) cholesterol (above 190 for adults or above 160 for children) and family history of high cholesterol, heart disease or stroke. Download the sample report @ https://www.pharmaproff.com/request-sample/1135 A very high level of LDL from birth leads to a twenty-fold increase in the risk of premature
Familial Amyloid Neuropathies Pharmaceutical and Healthcare Analysis Information
Summary Familial amyloid neuropathy is a slowly progressive condition characterized by the buildup of abnormal deposits of a protein called amyloid (amyloidosis) in the body's organs and tissues. Symptoms include numbness, tingling, pins and needles in the feet and hands, weakness and pain in the arms and legs, loss of sensation, urinary retention, reduced sweating, ankle swelling, fatigue, nausea, weight loss, dizziness and fainting. Supportive treatment includes diuretics, calcium channel blockers,
Familial Adenomatous Polyposis - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Familial Adenomatous Polyposis - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Familial Adenomatous Polyposis - Pipeline Review, H2 2017, provides an overview of the Familial Adenomatous Polyposis (Genetic Disorders) pipeline landscape. Familial adenomatous polyposis (FAP) or classic FAP is a genetic condition that causes extra
Familial Amyloid Cardiomyopathy Treatment Market - Global Industry Insights, Tre …
Aggregation and deposition of mutant and wild-type transthyretin protein (TTR) in heart results in familial amyloid cardiomyopathy, which typically occur after age of 60. Familial amyloid cardiomyopathy is also known as hereditary cardiac transthyretin amyloidosis or hereditary amyloid cardiomyopathy. The protein transthyretin amyloid fibrils infiltrate the myocardium that leads to diastolic dysfunction from restrictive cardiomyopathy, which eventually result to heart failure. There are several mutation in TTR which are associated
Familial Adenomatous Polyposis - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Familial Adenomatous Polyposis - Pipeline Review, H1 2017 to its growing collection of premium market research reports. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Familial Adenomatous Polyposis - Pipeline Review, H1 2017, provides an overview of the Familial Adenomatous Polyposis (Genetic Disorders) pipeline landscape. Familial adenomatous polyposis (FAP) is also known as familial polyposis coli, adenomatous polyposis coli, or
A Crown Jewel of Familial Integrated Advertising
In the communication business for 75 years: The Frankfurt WEFRA Werbeagentur GWA is celebrating its birthday. The recipe for success of the oldest German agency: Not to follow every trend, but to rely on experience and competence and still stay innovative. Whilst many agency owners sold their companies to large international networks, the agency which is still in familial hands, relies on independance. The grand age for the fast moving communication